Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
Yoshimasa Shiraishi(Kyushu University), Isamu Okamoto(Kyushu University Hospital), Motoko Tachihara(Kobe University), Nobuyuki Yamamoto(Wakayama Medical University), Osamu Hataji(Soka Municipal Hospital), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Katsuya Hirano(Hyogo Prefectural Amagasaki General Medical Center), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Tetsuya Mitsudomi(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kentaro Tanaka(Institute for the Future), Junji Kishimoto(Kyushu University Hospital)
Cited by 15
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k